Tyler Sandow

Join interventional oncologists Dr. Tyler Sandow from Ochsner Health and Dr. Nima Kokabi from UNC Chapel Hill as they delve into the intricacies of Y90 treatment planning. They discuss optimizing therapy through multidisciplinary tumor boards and collaboration between academic and private practices. The episode highlights their preferred dosimetry tools and imaging techniques like cone beam CT. Additionally, they explore the challenges of coordinating care and navigating insurance hurdles for liver cancer patients, emphasizing the need for meticulous planning and patient care.

Join interventional oncologists Dr. Tyler Sandow and Dr. Nima Kokabi as they dive deep into the intricacies of Y90 procedures. They tackle lung shunt fraction calculations, comparing SPECT CT with planar imaging for optimal dosing. Their discussion covers the nuances of various dosimetry models like BSA and voxel-based approaches. The duo also addresses high lung shunt management and the integration of advanced therapies such as TACE and SBRT, rounding it off with a compelling case study on individualized dosimetry planning for liver tumors.

Join interventional oncologists Drs. Tyler Sandow and Nima Kokabi as they dive into the fascinating world of single-session Y90 treatments for liver tumors. They discuss the latest insights on patient selection and the workflow involved in this innovative approach, highlighting its cost-effectiveness and safety profile. The doctors share practical tips for optimizing treatment and tackling challenges in the procedure. They even delve into real cases, exploring strategies that can enhance patient outcomes, including the potential for combined therapies.

Interventional radiologists Dr. Juan Gimenez and Dr. Tyler Sandow discuss managing hepatocellular carcinoma (HCC) in this episode. They delve into topics like lobar treatment vs. radiation segmentectomy, ablation and Y-90 combination, preoperative mapping, cone-beam CT, complex cases, treatment plans, and current research pursuits. Important points include new developments in tumor markers and the role of albumin in HCC. They also touch upon combination therapies, collaboration with oncologists, and the use of segmentectomy for metastatic disease.

Dr. Siddarth Padia, Dr. Tyler Sandow, Dr. Kavi Krishnasamy, and Dr. Kevin Burns share their journeys in interventional oncology, exploring how they transitioned from general radiology to specializing in liver cancer. They discuss innovative telehealth solutions and hybrid care models that enhance patient access and communication. The doctors emphasize the importance of clinic support and how integrating advanced technologies can drive procedural growth. Finally, they highlight the role of mentorship and relationship-building in overcoming challenges in establishing successful practices.